Neil Cooch

USPTO Granted Patents = 10 (Patent Applications = 6)

CIPO Patents = 3 (Patent Applications = 5)

EPO Patents = 1 (Patent Applications = 8)

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 4(Granted Patents)

Company Filing History:

10 out of 87

Inovio Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2021-2025

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12285473 - Cancer vaccines targeting MUC16 and uses thereof (2025-04-29),

2. 12161706 - Cancer vaccines targeting BORIS and uses thereof (2024-12-10),

3. 12064473 - Cancer vaccines targeting Survivin and uses thereof (2024-08-20),

4. 12054537 - Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies (2024-08-06),

5. 11986517 - Cancer vaccines targeting mesothelin and uses thereof (2024-05-21),

6. 11338029 - Cancer vaccines targeting PRAME and uses thereof (2022-05-24),

7. 11338028 - Cancer vaccines targeting LEMD1 and uses thereof (2022-05-24),

8. 11235044 - Cancer vaccines targeting MUC16 and uses thereof (2022-02-01),

9. 11154602 - Cancer vaccines targeting mesothelin and uses thereof (2021-10-26),

10. 11154601 - Cancer vaccines targeting BORIS and uses thereof (2021-10-26),

Title: The Innovative Contributions of Neil Cooch

Introduction

Neil Cooch, an accomplished inventor based in Oreland, Pennsylvania, has made significant strides in the field of biomedical innovations. With a portfolio of 10 patents, his work primarily focuses on developing novel cancer vaccines targeting specific antigens, showcasing his commitment to advancing cancer treatment options.

Latest Patents

One of Neil's most notable patents involves cancer vaccines targeting MUC16. This innovation encompasses nucleic acid molecules that encode a modified consensus MUC16 antigen, along with vectors, compositions, and vaccines designed to combat MUC16-expressing tumors. The patent outlines methods for treating and preventing tumors that express this antigen, which is pivotal in the effort to combat cancer.

Another critical patent from Neil is centered on cancer vaccines targeting BORIS. This patent similarly involves nucleic acid sequences encoding a synthetic consensus BORIS antigen, alongside corresponding vectors and compositions. The described methods aim to treat and prevent BORIS-expressing tumors, highlighting the versatility and importance of his research in the ongoing fight against cancer.

Career Highlights

Throughout his career, Neil Cooch has collaborated with reputable organizations such as Inovio Pharmaceuticals, Inc. and The Wistar Institute of Anatomy & Biology. His role in these institutions has allowed him to leverage cutting-edge technologies and research methodologies to contribute to his field.

Collaborations

Neil has worked alongside talented professionals, including Jian Yan and Anna Slager. These collaborations have enriched his research endeavors and enhanced the possibilities for innovative solutions in cancer treatment.

Conclusion

Neil Cooch's innovative contributions to cancer vaccine development position him as a noteworthy figure in the scientific community. His dedication to exploring new therapeutic pathways showcases the importance of invention in advancing medical science, ultimately aiming to provide better treatment options for patients battling cancer.

This text is generated by artificial intelligence and may not be accurate.